

Non-interventional post-authorization multi-database safety study to characterize the risk of angioedema and other specific safety events of interest in association with use of Entresto® (sacubitril/valsartan) in adult patients with heart failure

First published: 24/03/2017

Last updated: 11/07/2025

Study

Finalised

Administrative details

EU PAS number

EUPAS18214

Study ID

49019

DARWIN EU® study

No

Study countries

- Denmark
 - Germany
 - Italy
 - Netherlands
 - Spain
 - United Kingdom
-

Study description

Sacubitril/valsartan exhibits a novel mechanism of action to treat heart failure (HF) by simultaneously inhibiting neprilysin (neutral endopeptidase, NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and by blocking the angiotensin II type-1 (AT1) receptor via valsartan.

It was approved in the European Union (EU) in November 2015 for treatment of symptomatic chronic heart failure with reduced ejection fraction.

As agreed with the Committee for Medicinal Products for Human Use (CHMP), the Marketing Authorisation Holder of Sacubitril/valsartan conducted a non-imposed non-interventional Post-Authorization Safety Study (PASS, category 3) to estimate the incidence and relative risks of angioedema, as well as the incidence of hypotension, hyperkalaemia, hepatotoxicity, and renal impairment in adult patients diagnosed with HF (prevalent and incident) newly starting sacubitril/valsartan or using angiotensin-converting enzyme inhibitors (ACEIs). Therefore, a multi-database cohort study with secondary use of five European healthcare databases was performed.

The following databases were used: CPRD (The Clinical Practice Research Datalink) from the UK, PHARMO (The PHARMO Database Network) from the Netherlands, SIDIAP (Sistema d'Informació per al Desenvolupament de la Investigació en Atenció Primària) from Catalonia, Spain, HSD (Health Search IMS Health Longitudinal Patient Database) from Italy, and the Aarhus University Prescription Database and Danish National Patient Registry from Denmark.

Study status

Finalised

Research institutions and networks

Institutions

Novartis Pharmaceuticals

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Leibniz Institute for Prevention Research and Epidemiology - BIPS

Germany

First published: 29/03/2010

Last updated: 30/03/2026

Institution

Not-for-profit

ENCePP partner

The PHARMO Institute for Drug Outcomes Research (PHARMO Institute)

Netherlands

First published: 07/01/2022

Last updated: 19/12/2025

Institution

Non-Pharmaceutical company

ENCePP partner

Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, IDIAPJGol

Spain

First published: 05/10/2012

Last updated: 23/05/2025

Institution

Educational Institution

Laboratory/Research/Testing facility

Not-for-profit

ENCePP partner

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford

United Kingdom

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Educational Institution

Hospital/Clinic/Other health care facility

Aarhus University Hospital

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Società Italiana di Medicina Generale e delle Cure Primarie (SIMG)

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Patient organisation/association

Agenzia regionale di sanità della Toscana (ARS Toscana)

Italy

First published: 01/02/2024

Last updated: 23/03/2026

Institution

EU Institution/Body/Agency

ENCePP partner

Basel Pharmacoepidemiology Unit, University of Basel

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Contact details

Study institution contact

Novartis Clinical Disclosure Officer

Trialandresults.registries@novartis.com

Study contact

Trialandresults.registries@novartis.com

Primary lead investigator

Novartis Clinical Disclosure Officer

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 01/04/2017

Actual: 08/06/2017

Study start date

Planned: 30/06/2017

Actual: 01/09/2017

Date of interim report, if expected

Planned: 31/03/2018

Actual: 14/03/2018

Date of final study report

Planned: 25/11/2024

Actual: 09/10/2024

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

Novartis Pharma AG

Study protocol

[LCZ696B2014-Redacted-Protocol.pdf](#) (1.23 MB)

[LCZ696B2014-v01.1--protocol_15Sep2022_Redacted.pdf](#) (1.58 MB)

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)

Other study registration identification numbers and links

CLCZ696B2014

Methodological aspects

Study type

Study type list

Study type:

Non-interventional study

Scope of the study:

Safety study (incl. comparative)

Data collection methods:

Secondary use of data

Study design:

A non-interventional, cohort study using European healthcare database information in a population of adult patients with prevalent or incident HF, newly starting treatment with sacubitril/valsartan (with or without prior exposure to ACEIs or ARBs), or ACEIs (as new users, and prevalent users).

Main study objective:

The primary objectives of the study were:

- To estimate the incidence of specific safety events of interest in adult patients with HF newly starting treatment with sacubitril/valsartan (regardless of prior exposure to ACEIs or angiotensin receptor blockers [ARBs]).
- To estimate the incidence of all safety events of interest in adult HF patients newly starting treatment with sacubitril/valsartan without prior exposure to ACEIs or ARBs.

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Study drug International non-proprietary name (INN) or common name

SACUBITRIL

VALSARTAN

Anatomical Therapeutic Chemical (ATC) code

(C09DX04) valsartan and sacubitril

valsartan and sacubitril

Medical condition to be studied

Chronic left ventricular failure

Cardiac failure

Population studied

Short description of the study population

Adult patients with heart failure

Age groups

- Adults (18 to < 46 years)
 - Adults (46 to < 65 years)
 - Adults (65 to < 75 years)
 - Adults (75 to < 85 years)
 - Adults (85 years and over)
-

Estimated number of subjects

24000

Study design details

Outcomes

Angioedema was the primary safety event of interest, hypotension, hyperkalemia, hepatotoxicity, and renal impairment were secondary safety events of interest.

Data analysis plan

Demographic and baseline characteristics of patients initiating sacubitril/valsartan or ACEIs were described using contingency tables for categorical variables and mean, SD, range, median and IQR for continuous variables in each database.

The risk of the outcomes of interest was assessed as incidence rates (IRs) along with 95% confidence intervals (CIs) in users of sacubitril/valsartan and ACEIs. Exploratory: Adjusted relative risks of angioedema were estimated as hazard ratios (HRs) with 95% CIs among new users of sacubitril/valsartan, (a) who were treatment-naïve to ACEIs and ARBs, and (b) separately, in LCZ696 initiators regardless of prior ACEI or ARB use, relative to new users of ACEIs (treatment-naïve to ACEIs) by using Cox regression models.

Documents

Study report

[LCZ696B2014-Final-Study-Report_for redaction_Redacted.pdf](#) (2.8 MB)

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data source(s)

Clinical Practice Research Datalink

Danish registries (access/analysis)

Health Search/IQVIA Health Longitudinal Patient Database

The Information System for Research in Primary Care (SIDIAP)

PHARMO Data Network

German Pharmacoepidemiological Research Database

ARS Toscana

Data sources (types)

[Administrative healthcare records \(e.g., claims\)](#)

[Drug prescriptions](#)

[Electronic healthcare records \(EHR\)](#)

[Pharmacy dispensing records](#)

Use of a Common Data Model (CDM)

CDM mapping

Yes

CDM Mappings

CDM name (other)

study specific CDM

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

Unknown